ZA968767B - Pharmaceutically active compounds - Google Patents
Pharmaceutically active compoundsInfo
- Publication number
- ZA968767B ZA968767B ZA968767A ZA968767A ZA968767B ZA 968767 B ZA968767 B ZA 968767B ZA 968767 A ZA968767 A ZA 968767A ZA 968767 A ZA968767 A ZA 968767A ZA 968767 B ZA968767 B ZA 968767B
- Authority
- ZA
- South Africa
- Prior art keywords
- active compounds
- pharmaceutically active
- pharmaceutically
- compounds
- active
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9521231.2A GB9521231D0 (en) | 1995-10-17 | 1995-10-17 | Pharmaceutically active compounds |
| GBGB9602668.7A GB9602668D0 (en) | 1996-02-09 | 1996-02-09 | Pharmaceutically active compounds |
| GBGB9614386.2A GB9614386D0 (en) | 1996-07-09 | 1996-07-09 | Pharmaceutically active compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA968767B true ZA968767B (en) | 1997-04-17 |
Family
ID=27267949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA968767A ZA968767B (en) | 1995-10-17 | 1996-10-17 | Pharmaceutically active compounds |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5883102A (ja) |
| EP (1) | EP0858451A1 (ja) |
| JP (1) | JPH11513679A (ja) |
| KR (1) | KR19990064276A (ja) |
| CN (1) | CN1204327A (ja) |
| AR (1) | AR004219A1 (ja) |
| AU (1) | AU704133B2 (ja) |
| BR (1) | BR9610988A (ja) |
| CA (1) | CA2235304A1 (ja) |
| CZ (1) | CZ119398A3 (ja) |
| EE (1) | EE9800116A (ja) |
| HU (1) | HUP9900028A3 (ja) |
| IS (1) | IS4715A (ja) |
| NO (1) | NO310620B1 (ja) |
| NZ (1) | NZ319673A (ja) |
| PL (1) | PL326353A1 (ja) |
| SK (1) | SK45898A3 (ja) |
| TR (1) | TR199800697T2 (ja) |
| WO (1) | WO1997014686A1 (ja) |
| ZA (1) | ZA968767B (ja) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| SE9702534D0 (sv) | 1997-07-01 | 1997-07-01 | Astra Pharma Prod | Compounds |
| DE19731783A1 (de) * | 1997-07-24 | 1999-01-28 | Bayer Ag | Verfahren zur Herstellung von N-(5-Amino-2-cyano-4-fluor-phenyl)-sulfonamiden und neue Zwischenprodukte |
| EP1087770A4 (en) | 1998-06-15 | 2001-11-14 | Merck & Co Inc | PRENYL PROTEIN TRANSFERASE INHIBITORS |
| SE9802333D0 (sv) | 1998-06-29 | 1998-06-29 | Astra Pharma Prod | Novel combination |
| PL346860A1 (en) * | 1998-09-08 | 2002-03-11 | Monsanto Co | Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors |
| SE0000477D0 (sv) * | 2000-02-14 | 2000-02-14 | Astrazeneca Canada Inc | Novel compounds |
| US6482829B2 (en) * | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
| US6534220B2 (en) | 2000-12-29 | 2003-03-18 | 3M Innovative Properties Company | High-boiling electrolyte solvent |
| WO2002076953A1 (en) * | 2001-03-21 | 2002-10-03 | Warner-Lambert Company Llc | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| US20040006111A1 (en) * | 2002-01-25 | 2004-01-08 | Kenneth Widder | Transmucosal delivery of proton pump inhibitors |
| CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| AU2003263323A1 (en) * | 2002-09-07 | 2004-03-29 | Celltech R And D Limited | Quinazolinone derivatives |
| US20040248942A1 (en) * | 2003-02-20 | 2004-12-09 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| WO2005007117A2 (en) * | 2003-07-18 | 2005-01-27 | Santarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| CA2531564C (en) * | 2003-07-18 | 2016-01-19 | Santarus, Inc. | Pharmaceutical composition for inhibiting acid secretion |
| US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| AU2005225471B2 (en) * | 2004-03-26 | 2011-05-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US8906940B2 (en) * | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| PL1879573T3 (pl) * | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| RU2416603C9 (ru) | 2005-10-25 | 2012-06-20 | Сионоги Энд Ко., Лтд. | Производные аминодигидротиазина |
| TW200804290A (en) * | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2007138612A2 (en) * | 2006-05-25 | 2007-12-06 | Vittal Mallya Scientific Research Foundation | A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4- yl]-(3-ethynylphenyl)amine hydrochloride |
| WO2007138613A2 (en) * | 2006-05-25 | 2007-12-06 | Vittal Mallya Scientific Research Foundation | A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| EP2147914B1 (en) | 2007-04-24 | 2014-06-04 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivatives substituted with cyclic groups |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| DE102007038250A1 (de) * | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellverfahren |
| WO2009151098A1 (ja) | 2008-06-13 | 2009-12-17 | 塩野義製薬株式会社 | βセクレターゼ阻害作用を有する含硫黄複素環誘導体 |
| PL2315756T3 (pl) | 2008-07-08 | 2015-02-27 | Incyte Holdings Corp | 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy |
| CN102186841A (zh) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
| TWI488852B (zh) | 2009-12-11 | 2015-06-21 | Shionogi & Co | 衍生物 |
| US20120258961A1 (en) * | 2009-12-24 | 2012-10-11 | Shionogi & Co., Ltd. | 4-amino-1,3-thiazine or oxazine derivative |
| JP5816630B2 (ja) | 2010-10-29 | 2015-11-18 | 塩野義製薬株式会社 | ナフチリジン誘導体 |
| JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
| UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2013096744A1 (en) * | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| DK3066085T3 (da) | 2013-11-08 | 2020-06-02 | Incyte Holdings Corp | Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor |
| WO2025024605A1 (en) * | 2023-07-25 | 2025-01-30 | University Of Florida Research Foundation, Incorporated | Rev-erb antagonists |
-
1996
- 1996-10-14 NZ NZ319673A patent/NZ319673A/en unknown
- 1996-10-14 EP EP96933545A patent/EP0858451A1/en not_active Withdrawn
- 1996-10-14 HU HU9900028A patent/HUP9900028A3/hu unknown
- 1996-10-14 SK SK458-98A patent/SK45898A3/sk unknown
- 1996-10-14 EE EE9800116A patent/EE9800116A/xx unknown
- 1996-10-14 BR BR9610988A patent/BR9610988A/pt unknown
- 1996-10-14 TR TR1998/00697T patent/TR199800697T2/xx unknown
- 1996-10-14 PL PL96326353A patent/PL326353A1/xx unknown
- 1996-10-14 JP JP9515588A patent/JPH11513679A/ja active Pending
- 1996-10-14 CZ CZ981193A patent/CZ119398A3/cs unknown
- 1996-10-14 CN CN96198998A patent/CN1204327A/zh active Pending
- 1996-10-14 CA CA002235304A patent/CA2235304A1/en not_active Abandoned
- 1996-10-14 KR KR1019980702767A patent/KR19990064276A/ko not_active Withdrawn
- 1996-10-14 AU AU72243/96A patent/AU704133B2/en not_active Ceased
- 1996-10-14 US US08/793,713 patent/US5883102A/en not_active Expired - Fee Related
- 1996-10-14 WO PCT/GB1996/002496 patent/WO1997014686A1/en not_active Ceased
- 1996-10-15 AR ARP960104753A patent/AR004219A1/es unknown
- 1996-10-17 ZA ZA968767A patent/ZA968767B/xx unknown
-
1998
- 1998-04-15 IS IS4715A patent/IS4715A/is unknown
- 1998-04-16 NO NO19981710A patent/NO310620B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5883102A (en) | 1999-03-16 |
| EE9800116A (et) | 1998-10-15 |
| BR9610988A (pt) | 1999-04-06 |
| NO981710L (no) | 1998-06-03 |
| HUP9900028A2 (hu) | 1999-04-28 |
| NO310620B1 (no) | 2001-07-30 |
| CN1204327A (zh) | 1999-01-06 |
| CZ119398A3 (cs) | 1998-09-16 |
| JPH11513679A (ja) | 1999-11-24 |
| CA2235304A1 (en) | 1997-04-24 |
| SK45898A3 (en) | 1999-01-11 |
| WO1997014686A1 (en) | 1997-04-24 |
| AR004219A1 (es) | 1998-11-04 |
| NZ319673A (en) | 2000-06-23 |
| MX9802926A (ja) | 1998-08-01 |
| PL326353A1 (en) | 1998-09-14 |
| KR19990064276A (ko) | 1999-07-26 |
| TR199800697T2 (xx) | 1998-07-21 |
| AU7224396A (en) | 1997-05-07 |
| IS4715A (is) | 1998-04-15 |
| EP0858451A1 (en) | 1998-08-19 |
| HUP9900028A3 (en) | 1999-11-29 |
| AU704133B2 (en) | 1999-04-15 |
| NO981710D0 (no) | 1998-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA968767B (en) | Pharmaceutically active compounds | |
| GB9526511D0 (en) | Pharmaceutically active compounds | |
| GB9507641D0 (en) | Pharmaceutically active compounds | |
| GB9500427D0 (en) | Pharmaceutically active compounds | |
| GB9501122D0 (en) | Pharmaceutically active compounds | |
| GB9518486D0 (en) | Pharmaceutically active compounds | |
| GB9502429D0 (en) | Pharmaceutically active compounds | |
| GB9502541D0 (en) | Pharmaceutically active compounds | |
| GB9502668D0 (en) | Pharmaceutically active compounds | |
| GB9502669D0 (en) | Pharmaceutically active compounds | |
| GB9502670D0 (en) | Pharmaceutically active compounds | |
| GB9505076D0 (en) | Pharmaceutically active compounds | |
| GB9505677D0 (en) | Pharmaceutically active compounds | |
| GB9500099D0 (en) | Pharmaceutically active compounds | |
| GB9514396D0 (en) | Pharmaceutically active compounds | |
| GB9502229D0 (en) | Pharmaceutically active compounds | |
| GB9509942D0 (en) | Pharmaceutically active compounds | |
| GB9510406D0 (en) | Pharmaceutically active compounds | |
| GB9510461D0 (en) | Pharmaceutically active compounds | |
| GB9510468D0 (en) | Pharmaceutically active compounds | |
| GB9513686D0 (en) | Pharmaceutically active compounds | |
| GB9513745D0 (en) | Pharmaceutically active compounds | |
| GB9513775D0 (en) | Pharmaceutically active compounds | |
| GB9506274D0 (en) | Pharmaceutically active compounds | |
| GB9515884D0 (en) | Pharmaceutically active compounds |